1,3-butanediol diacetoacetate | 58213-75-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: 1,3-butanediol diacetoacetate
• 英文别名: (R,S)-1,3-butanediol acetoacetate diester；3-(3-Oxobutanoyloxy)butyl 3-oxobutanoate
• CAS: 58213-75-5
• 化学式: C₁₂H₁₈O₆
• 分子量: 258.271
• InChiKey: MDOKNTXSIGQKCJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  18
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  86.7
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1,3-butanediol diacetoacetate 、 1,3-丁二醇 在 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 以61.4 %的产率得到butane-1,3-diyl bis(2-(2,4-dimethyl-1,3-dioxan-2-yl)acetate)
  参考文献：
  名称：

  WO2023/94654

  摘要：

  公开号：
• 作为产物：
  描述：

  双乙烯酮 、 1,3-丁二醇 在 sodium acetate 、 溶剂黄146 作用下， 生成 1,3-butanediol diacetoacetate
  参考文献：
  名称：

  Process of preparing acetoacetic esters

  摘要：

  公开号：

  US02351366A1

文献信息

• [EN] LACTATE/KETONE BODY ESTERS<br/>[FR] ESTERS CORPORELS DE LACTATE/CÉTONE
  申请人：UNIV AARHUS

  公开号：WO2022096637A1

  公开（公告）日：2022-05-12

  The present invention relates to a Lactate/Ketone body ester for preservation of vital organ function and combat inflammation and cancer growth. In particular, the present invention relates to a Lactate/Ketone body ester with the beneficial properties of Lactate and beta-hydroxybutyrate (BHB) on vital organ function, inflammation and cancer growth but without the harmful sodium loads following administration of both Lactate and beta-hydroxybutyrate.

  本发明涉及一种乳酸/酮体酯，用于保护重要器官功能、抗炎和抑制癌症生长。具体而言，本发明涉及一种乳酸/酮体酯，具有乳酸和β-羟基丁酸酯（BHB）对重要器官功能、炎症和癌症生长的有益特性，但不会在两者治疗后产生有害的钠负荷。
• Exogenous ketone supplements for reducing anxiety-related behavior
  申请人：University of South Florida

  公开号：US10980764B1

  公开（公告）日：2021-04-20

  Methods of treating anxiety disorders or reducing anxiety-related behaviors. The methods include administering a therapeutically effective amount of ketone supplementation, such as butanediol, ketone esters (e.g., 1,3-butanediol-acetoacetate diester) and/or ketone salts (e.g., beta-hydroxybutyrate-mineral salt), chronically, sub-chronically, or acutely, with or without admixture with a medium chain triglyceride or in combination. It was determined herein that ketone supplementation reduced anxiety in rats on elevated plus maze as measured by less entries to closed arms, more time spent in open arms, more distance travelled in open arms, and delayed latency to entrance to closed arms, when compared to control. Along with reducing anxiety-related behavior, the chronic, sub-chronic, and acute ketone supplements also caused significant elevation of blood βHB levels and changed blood glucose levels.

  治疗焦虑症或减少焦虑相关行为的方法。这些方法包括慢性、亚慢性或急性服用治疗有效量的酮补充剂，如丁二醇、酮酯（如 1,3-丁二醇-乙酰乙酸二酯）和/或酮盐（如β-羟基丁酸矿盐），与中链甘油三酯混合或不与中链甘油三酯混合或混合服用。研究发现，与对照组相比，补充酮可减少大鼠在高架加迷宫中的焦虑，具体表现为进入封闭臂的次数减少、在开放臂中花费的时间增加、在开放臂中行进的距离增加以及进入封闭臂的潜伏期推迟。在减少焦虑相关行为的同时，慢性、亚慢性和急性酮补充剂还能显著提高血液中的βHB水平，并改变血糖水平。
• Methods and compositions for supporting renal health
  申请人：The Regents of the University of California

  公开号：US11013705B2

  公开（公告）日：2021-05-25

  Compositions and methods for supporting health, especially renal health, comprising ketonic agents that recapitulate beneficial effects of ketosis by exogenously administered agents. The agents include BHB, analogs thereof, and GPR109A agonists. The agents may further include crystal precipitation inhibitors which synergistically improve treatment of certain renal conditions. The agents may be used in dietary supplements and therapeutic compositions for the treatment of cystic kidney diseases such as polycystic kidney disease, ciliopathies, and other conditions.

  支持健康（尤其是肾脏健康）的组合物和方法，包括通过外源给药剂重现酮病有益效果的酮剂。这些制剂包括 BHB、其类似物和 GPR109A 激动剂。这些制剂还可包括晶体沉淀抑制剂，可协同改善某些肾脏疾病的治疗。这些制剂可用于膳食补充剂和治疗组合物，以治疗囊性肾病，如多囊肾、纤毛虫病和其他疾病。
• Dietary and natural product management of negative side effects of cancer treatment
  申请人：UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.

  公开号：US11020372B2

  公开（公告）日：2021-06-01

  The invention relates to novel methods and compositions for safely reducing negative side effects of cancer treatments. These methods and compositions comprise administering to a patient a composition comprising one or more of the following: curcumin (derived from turmeric), epigallocatechin-3-gallate (EGCG, enriched in green tea), glucosinolates (enriched in cruciferous vegetables) and/or derivatives thereof, such as sulforaphane (SFN), alone or combined with a ketogenic diet or a modified ketogenic diet. Also the current invention relates to a composition comprising medium chain triglycerides (MCT), Epigallocatechin-3-gallate, curcumin, compositions comprising glucosinolates and/or derivatives thereof, such as sulforaphane (SFN). The invention provides that administering a composition comprising curcumin, EGCG, sulforaphane, alone or combined with a ketogenic diet or a modified ketogenic diet (low carbohydrate diet) alone or supplemented with MCT improves resistance of normal cells to cytotoxicity of cancer treatments, in turn, reducing their negative side effects. Increasing normal cells, tissues or organs' resistance to chemotherapeutic agents, the invention improves patients' tolerance to anti-cancer treatments' toxicity, which, in turn, contributes to enhance their efficacy, leading to increased survival of the subject treated with the current invention.

  本发明涉及用于安全减少癌症治疗负面副作用的新型方法和组合物。这些方法和组合物包括向患者施用包含以下一种或多种成分的组合物：姜黄素（源自姜黄）、表没食子儿茶素-3-棓酸盐（EGCG，富含于绿茶中）、葡萄糖苷酸盐（富含于十字花科蔬菜中）和/或其衍生物，如莱菔硫烷（SFN），单独施用或与生酮饮食或改良生酮饮食结合施用。本发明还涉及一种包含中链甘油三酯（MCT）、表没食子儿茶素-3-棓酸盐、姜黄素、包含葡萄糖苷酸盐和/或其衍生物（如莱菔硫烷（SFN））的组合物。本发明提供了一种由姜黄素、表没食子儿茶素-3-棓酸盐、莱菔硫烷组成的组合物，单独使用或与生酮饮食或改良生酮饮食（低碳水化合物饮食）结合使用，或单独使用或补充 MCT，可提高正常细胞对癌症治疗的细胞毒性的抵抗力，进而减少其负面副作用。本发明提高了正常细胞、组织或器官对化疗药物的抵抗力，改善了患者对抗癌治疗毒性的耐受性，这反过来又有助于提高其疗效，从而提高了接受本发明治疗的患者的存活率。
• Migraine prevention and treatment
  申请人：UNIVERSITATS-KINDERSPITAL

  公开号：US11166928B2

  公开（公告）日：2021-11-09

  The invention relates to a compound for use in a method of treatment or prevention of migraine and/or symptoms thereof. The compound is selected from beta-hydroxybutyric acid (βHB) or a pharmaceutically acceptable salt thereof, acetoacetate (AcAc) or a pharmaceutically acceptable salt thereof, a metabolic precursor of βHB or AcAc 1,3-butanedio and a compound comprising an acetoacetyl- or 3-hydroxybutyrate moiety. The invention further relates to a pharmaceutical composition comprising βHB, AcAc or a pharmaceutically acceptable salt thereof.

  本发明涉及一种用于治疗或预防偏头痛和/或偏头痛症状的化合物。该化合物选自β-羟基丁酸（βHB）或其药学上可接受的盐、乙酰乙酸酯（AcAc）或其药学上可接受的盐、βHB或AcAc的代谢前体1,3-丁二酸和包含乙酰乙酰基或3-羟基丁酸分子的化合物。本发明还涉及一种药物组合物，其中包含 βHB、AcAc 或其药学上可接受的盐。